

REMARKS

Applicants hereby offer preliminary amendments to the present application to place the application in better form for allowance.


Applicants have canceled Claims 1-6 in favor of replacement Claims 7-11 to correct certain informalities (including avoidance of use claims) and to clarify the intended meaning of the claims without materially altering their scope. Applicants respectfully submit that the claims are fully supported in the specification.

Applicants have amended the specification to capitalize all letters in the title and to insert a statement of priority. Applicants submit that these amendments serve only to clarify their application and do not alter the scope of their disclosure.

Applicants have amended the Abstract to change the title for the reasons discussed above and to change the heading and body to a more customary form. A copy of the new Abstract is separately attached.

In view of the preceding amendments and remarks, allowance of the claims is respectfully requested.

Respectfully submitted,

By 


Raymond J. Harmuth
Attorney for Applicant(s)
Reg. No. 33,896

Bayer CropScience LP
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
PHONE: (412) 777-3916
FACSIMILE PHONE NUMBER:
412-777-3902
s/rmc/rjh/0417



TRIAZOLOPYRIMIDINES
ABSTRACT OF THE DISCLOSURE

This invention relates to novel triazolopyrimidines of the formula



in which G, R and X are as defined in the disclosure,
to a process for preparing these substances and to their use for controlling unwanted
microorganisms.